<DOC>
	<DOCNO>NCT00980356</DOCNO>
	<brief_summary>The purpose study determine whether monotherapy Vildagliptin improve glycemic control kidney transplant patient newly diagnose New Onset Diabetes Transplantation ( NODAT ) .</brief_summary>
	<brief_title>Vildagliptin New Onset Diabetes After Transplantation</brief_title>
	<detailed_description>Development new onset diabetes mellitus transplantation ( NODAT ) also call post-transplant diabetes mellitus ( PTDM ) increase risk cardiovascular disease poor short term clinical outcome . There currently doubt fact NODAT condition need medical attention treatment . Although center follow treatment regimen DM type II prospective data effectiveness NODAT lacking . Little information exist kidney transplantation regard conventional glucose-lowering therapy , either oral hypoglycemic agent traditional insulin regimen . The Aim study evaluate whether monotherapy Vildagliptin improve glycemic control ass safety kidney transplant patient newly diagnose NODAT .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>• Newly diagnose NODAT define pathologic OGTT ( 2h , 75mg glucose ) : glucose ≥ 200mg/dl renal transplantation ( deceased living donor ) treatment standard immunosuppression center , consist triple therapy tacrolimus cyclosporine A , mycophenolate mofetil azathioprine , prednisone . stable graft function 6 month post transplant . informed consent patient patient prior history type 1 type 2 diabetes body mass index ( BMI ) &gt; 40 pregnancy severe renal impairment ( GFR &lt; 30 mL/min./1.73 m2 ) severe liver impairment severe blood glucose elevation need therapy insulin HbA1c &gt; 8.5 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Diabetes Kidney transplantation</keyword>
	<keyword>New onset diabetes mellitus transplantation</keyword>
</DOC>